Mednet Logo
CommunityCardiology

Would you consider using DOACs as a bridge to warfarin instead of heparin or LMWH?

For example, would you consider this method in an ESRD/HD patient with antiphospholipid syndrome who had a major bleed requiring reversal of warfarin that then needs to be bridged back to warfarin after bleeding is stabilized?
Community PollStarted

What agents would you use to bridge to warfarin?

122 physicians have voted

Join Mednetto vote and see how they answered.

4 Answers
Mednet Member
Mednet Member
Cardiology · Hunterdon Cardiovascular Associates
Answered on

I would feel very comfortable bridging with apixaban, given its relatively short half-life and fairly quick absorption. I think it is very similar to bridging with Lovenox.

More importantly, it usually takes at least 24 hours until heparin IV gets to therapeutic levels - it is often too high or too ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Hematology · Mayo Clinic
Answered on

This is an interesting question. My bias would be to bridge back to warfarin under cover of IV unfractionated heparin. Each DOAC has a different elimination route with approximate renal elimination as follows: dabigatran: 80%; edoxaban: 50%; rivaroxaban: 33%; apixaban: 25% (Baker et al., PMID 392236...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Hematology · Medical University of South Carolina
Answered on

After 3 months of anticoagulation for APSy, the estimated annual risk of VTE recurrence is about 5% max; this converts into ~0.01% risk/day. On the other hand, the serious bleeding risk with bridging is about 1-2% per day in patients with ESRD/HD (even in the setting of mechanical valve, the estimat...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Neurology · University of Virginia, School of Medicine
Answered on

I think from a stroke prevention standpoint it depends on the etiology. If someone has a mechanical valve or anti-phospholipid antibody syndrome then this approach may not help significantly for prevention, since the trials in these conditions evaluating the efficacy of DOACs did not he...

Join for free or sign in to see the full answer